Aspira Women’s Health Appoints Mr. John Ragard to its Board of Directors
July 29 2024 - 8:00AM
Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a
bio-analytical based women’s health company focused on the
development of gynecologic disease diagnostic tools, today
announced the appointment of Mr. John Ragard to its Board of
Directors. Mr. Ragard is an accomplished executive with extensive
experience successfully managing several billion-dollar portfolios
over his career.
“We are pleased to welcome John to our Board of Directors,” said
Ms. Jannie Herchuk, Chairwoman of the Board at Aspira Women’s
Health. “John brings a wealth of experience and a keen
understanding of Wall Street, having been a successful money
manager for the past four decades. He will be an important voice on
our Board as we continue to build Aspira to be a world-class
company delivering a new standard of care in women’s health.”
Nicole Sandford, Chief Executive Officer of Aspira Women’s
Health said, “John is an excellent addition to the Board. As a
seasoned investment professional, John understands what Aspira
needs to do to attract and retain long-term investors. He has
followed the company closely for many years and, as a result, will
quickly add valuable insight to help us execute the next phase of
accelerated growth.”
Mr. John Ragard spent over 46 years as a venture capital
investor, public equity buy-side analyst, and portfolio manager.
Mr. Ragard is currently a Senior Investment Advisor at Wayve
Capital Management after having been a portfolio manager at
Spouting Rock for over six years, where he co-managed a small-cap
growth portfolio that outperformed the benchmark over the 5-year
and since-inception periods. Prior to Spouting Rock, Mr. Ragard was
a portfolio manager at Friess Associates where he outperformed the
Russell 3000 Growth Index by over 400 basis points annually for
over 20 years. Mr. Ragard received his Bachelor of Science in
Economics cum laude from the Wharton School and is a Chartered
Financial Analyst.
Mr. Ragard added, “I am excited to join this group of committed
directors. I have long believed in the promise of Aspira’s
compelling portfolio, and I look forward to working closely with
them as we take the company to the next level.”
About Aspira Women’s Health Inc.Aspira Women’s
Health Inc. is dedicated to the discovery, development, and
commercialization of noninvasive, AI-powered tests to aid in the
diagnosis of gynecologic diseases.
OvaWatch® and Ova1Plus® are offered to clinicians as OvaSuiteSM.
Together, they provide the only comprehensive portfolio of blood
tests to aid in the detection of ovarian cancer for the 1.2+
million American women diagnosed with an adnexal mass each year.
OvaWatch provides a negative predictive value of 99% and is used to
assess ovarian cancer risk for women where initial clinical
assessment indicates the mass is indeterminate or benign, and thus
surgery may be premature or unnecessary. Ova1Plus is a reflex
process of two FDA-cleared tests, Ova1® and Overa®, to assess the
risk of ovarian malignancy in women planned for
surgery.
Our in-development test pipeline is designed to expand our
ovarian cancer portfolio and addresses the tremendous need for
noninvasive diagnostics for endometriosis, a debilitating disease
that impacts millions of women worldwide. In ovarian cancer, our
OvaMDxSM risk assessment is designed to combine microRNA and
protein biomarkers with patient data to further enhance the
sensitivity and specificity of our current tests. In endometriosis,
EndoCheckSM is the first-ever noninvasive test designed to identify
endometriomas, one of the most commonly occurring forms of
endometriosis. The EndoMDxSM test is designed to combine microRNA
and protein biomarkers with patient data to identify all
endometriosis.
Forward-Looking StatementsThis press release
contains forward-looking statements, as defined in the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements involve a number of risks and uncertainties. Such
forward-looking statements include statements regarding, among
other things, the timing and completion of any products in the
pipeline development and other statements that are predictive in
nature. Actual results could differ materially from those discussed
due to known and unknown risks, uncertainties, and other factors.
These forward-looking statements generally can be identified by the
use of words such as “designed to,” “expect,” “plan,” “anticipate,”
“could,” “may,” “intend,” “will,” “continue,” “future,” other words
of similar meaning and the use of future dates. Forward-looking
statements in this press release and other factors that may cause
such differences include the satisfaction of customary closing
conditions related to the offering and the expected timing of the
closing of the offering. These and additional risks and
uncertainties are described more fully in the company’s filings
with the SEC, including those factors identified as “Risk Factors”
in our most recent Annual Report on Form 10-K, for the fiscal year
ended December 31, 2023, and subsequent Quarterly Reports on Form
10-Q. If any of these risks materialize or our assumptions prove
incorrect, actual results could differ materially from the results
implied by these forward-looking statements. There may be
additional risks that Aspira presently does not know, or that
Aspira currently believes are immaterial, that could also cause
actual results to differ from those contained in the
forward-looking statements. In addition, forward-looking statements
reflect Aspira’s expectations, plans, or forecasts of future events
and views as of the date of this press release. Subsequent events
and developments may cause the Company’s assessments to change.
However, while Aspira may elect to update these forward-looking
statements at some point in the future, Aspira expressly disclaims
any obligation to do so, except as required by law. These
forward-looking statements should not be relied upon as
representing Aspira’s assessments of any date after the date of
this press release. Accordingly, undue reliance should not be
placed upon the forward-looking statements.
Investor Relations Contact: Nicole
Sandford Chief Executive OfficerInvestors@aspirawh.com
Aspira Womans Health (NASDAQ:AWH)
Historical Stock Chart
From Sep 2024 to Oct 2024
Aspira Womans Health (NASDAQ:AWH)
Historical Stock Chart
From Oct 2023 to Oct 2024